Inventiva (IVA) – Globe Newswire
-
Correction: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update
-
Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update
-
Inventiva reports 2023 First Quarter Financial Information¹ and provides a corporate update
-
Inventiva announces filing of its 2022 Universal Registration Document and 2022 Annual Report on Form 20-F
-
Inventiva reports its 2022 full-year results
-
Inventiva announces the schedule of publication and presentation of its 2022 Full-Year Financial Results
-
Correction: Inventiva reports preliminary financial results for Full-Year 2022¹
-
Inventiva reports preliminary financial results for Full-Year 2022¹
-
Inventiva announces changes to the clinical development of lanifibranor, including plans for a new Phase III trial in patients with NASH and compensated cirrhosis
-
Inventiva draws down €25 million tranche under Finance Contract with the European Investment Bank
-
Inventiva secures a new patent expanding the IP protection of its lead product candidate lanifibranor in the US
-
Inventiva announces a new Director of the Board of Directors
-
Inventiva reports 2022 Third Quarter Financial Information¹
-
Inventiva provides an update on the development of cedirogant by AbbVie
-
Inventiva announces a scientific presentation at the AASLD The Liver Meeting® 2022
-
Inventiva reports its 2022 first-half financial results and provides a corporate update
-
Inventiva and Sino Biopharm announce licensing and collaboration agreement to develop and commercialize lanifibranor in Greater China
-
Inventiva announces the schedule of publication and presentation of its 2022 Half-Year Financial Results
-
Inventiva Reports 2022 First-Half Financial Information¹
-
Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 19 May 2022
-
Inventiva reports 2022 First Quarter Financial Information and provides clinical development update
-
Inventiva secures a €50 million credit facility from the European Investment Bank
-
Inventiva announces the presentation of a scientific abstract at the next International Conference on Fatty Liver
-
Inventiva announces that its IND application for the Phase II combination trial with lanifibranor and empagliflozin in patients with NASH and T2D has been accepted by the FDA
-
Inventiva reports its 2021 Full-Year Results: key milestones achieved with lanifibranor in NASH and cedirogant in psoriasis
-
Inventiva publie ses résultats annuels 2021 : Avancées majeures avec lanifibranor dans la NASH et cedirogant dans le psoriasis
-
Inventiva announces participation at several conferences in March 2022
-
Inventiva announces the schedule of publication and presentation of its 2021 Full-Year Financial Results
-
Inventiva reports cash position and revenues for Full-Year 2021
-
Inventiva receives a €4 million milestone payment from AbbVie for cedirogant Phase IIb initiation
-
Inventiva announces participation at several conferences in January and February 2022
-
Inventiva to present at the 40th Annual J.P. Morgan Healthcare Conference
-
Inventiva announces positive results of clinical thorough QT study conducted with lanifibranor
-
Inventiva reports 2021 Third Quarter Financial Information
-
Inventiva to host a webcast with Key Opinion Leaders from the AASLD The Liver Meeting™ 2021
-
Inventiva announces participation at several conferences in November 2021
-
Inventiva announces the design of LEGEND, a Phase IIa combination trial with lanifibranor and SGLT2 inhibitor empagliflozin in patients with NASH and type 2 diabetes
-
The New England Journal of Medicine publishes the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASH
-
Inventiva announces the presentation of five scientific abstracts at the AASLD The Liver Meeting™ 2021
-
Inventiva announces participation at several investor conferences in October 2021
-
Inventiva completes sale of $30 million through its ATM program to existing and new specialized institutional investors
-
Inventiva announces FDA decision that Fast Track designation granted to lanifibranor in NASH encompasses the treatment of NASH with compensated cirrhosis
-
Inventiva reports 2021 first half financial results and provides a corporate update
-
Inventiva announces major recruitments to accelerate the development of lanifibranor in NASH
-
Inventiva’s 2021 First-Half Financial Results Presentation
-
Inventiva announces the initiation of its pivotal Phase III clinical trial evaluating lanifibranor in NASH
-
Inventiva announces participation at several investor conferences in September 2021
-
Inventiva announces the implementation of an At-The-Market program in the United States
-
Inventiva Reports First-Half of 2021 Financial Information
-
Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2021 and during a KOL webcast event
Back to IVA Stock Lookup
